Acute Conjunctivitis Treatment Market
Acute Conjunctivitis Treatment Market, or pink eye, is an irritation or inflammation of the conjunctiva that covers the white part of the eyeball. It can be caused by allergies or a bacterial or viral infection. Acute Conjunctivitis Treatment Market can be highly communicable and can be spread easily by the contact with secretions of eye from the infected person. Conjunctivitis often resolves on its own, but treatment can speed up the recovery process. Allergic conjunctivitis can be treated with antihistamines. Bacterial conjunctivitis can be treated with antibiotic eye drops.
Acute Conjunctivitis Treatment Market is growing due to increase of aging population, increase in ophthalmic diseases prevalence rate, rise in investments for the development of new products, growing conscious towards health, funded eye check-up campaigns by governments of different countries are driving the growth of allergic conjunctivitis treatment market. Moreover, increasing awareness about various eye infections and rise in blindness prevalence among geriatric population boosting the growth of allergic conjunctivitis treatment market. However, due to the stringent regulations in drugs developmental process and side effects associated with the various antibiotics would hamper the adoption of eye infection pharmaceutical treatment, in turn, hinder the growth of bacterial conjunctivitis treatment market.
The global acute conjunctivitis treatment market is categorized as-
- Type of conjunctivitis
- Viral Conjunctivitis
- Bacterial Conjunctivitis
- Allergic Conjunctivitis
- Conjunctivitis Caused by Irritants
- Dosage form
- Gels and Cream
- Eye drops
- Tablets and Capsules
- Drug class
- Antihistamines
- Antibiotic
- Mast cell stabilizers
- Anti-inflammatory drugs
- Others
- End-users
Hospital, retail and online pharmacies
And finally on the basis of geographical regions, the global acute conjunctivitis treatment market is divided into five major regions-North America, Europe, the Middle East & Africa and Latin America. North America is dominating global bacterial conjunctivitis treatment market owing to few factors like rising more number of approvals by FDA, various strong strategies by pharma companies, rise in R&D investments. The European market is the second largest in allergic conjunctivitis market. Increase in prevalence and growing awareness of conjunctivitis and its treatments are leading the growth of Asia Pacific allergic conjunctivitis treatment market. The Middle East and Africa allergic conjunctivitis market is expected to have limited growth because of lack of traditional healthcare practices and slow adoption of new products and therapies.
Some of the key players in global acute conjunctivitis treatment market are Pfizer, Inc. (U.S), Allergan Inc. (Ireland), Boehringer Ingelheim GmbH (Germany), CIBA Vision Ophthalmics (U.S), Sanofi (France), Novartis AG (Switzerland), Bausch & Lomb Inc. (Valeant) (Canada), Merck & Co., Inc. (U.S), and Santen Pharmaceuticals Co. Ltd.(Japan). For e.g. in 2017, Teva Pharmaceuticals launched, generic version of Pataday (olopatadine hydrochloride ophthalmic solution) 0.2%, in U.S used to treat Allergic conjunctivitis.
As per the clinical study conducted by scientists Neal P. Barney and Amir A. Azari in 2013, which was published in Journal of American Medical Association (JAMA), states that bacterial conjunctivitis accounts for about 50% of conjunctivitis cases in U.S. and also estimated that the bacterial conjunctivitis incidence rate was anticipated as 135 in 10,000.Top pharma companies are dominating the market owing to different factors like sale, strong global presence, and efficient distribution network, R&D investments, products of superior quality, and strong brand image. In 2016, Irish based pharma company Shire'™s Xiidra received U.S.FDA approval which is used to treat dry-eye.